GlassScriptPhysician profile
Rahul S Pansare
NPI 1336660851
$4,907.49
in general payments reported to CMS, 2019-2025
30 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $397 · 2023: $1,290 · 2024: $1,634 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,225 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.07 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,148.14 | 2021-2025 | Minimed 780g, Guardian Sensor (3) |
| Novo Nordisk INC | $499.27 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $305.92 | 2021-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $246.60 | 2023-2025 | |
| Dexcom, INC. | $211.61 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Insulet Corporation | $206.68 | 2023-2025 | Omnipod, Omnipod |
| Recordati_rare_diseases_inc. | $203.28 | 2023-2025 | Isturisa |
| Alexion Pharmaceuticals, INC. | $188.36 | 2023-2025 | Strensiq |
| Radius Health, INC. | $175.41 | 2023-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $172.41 | 2023-2025 | |
| Lilly USA, LLC | $167.71 | 2024 | Jardiance, Zepbound |
| Amryt Pharma Holdings LTD | $139.08 | 2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $139.03 | 2022-2023 | |
| Abbvie INC. | $127.08 | 2023-2025 | |
| Abbott Laboratories | $120.78 | 2023-2025 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $120.20 | 2023 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.68 | 2023-2024 | Jardiance |
| Corcept Therapeutics | $112.03 | 2024-2025 | Korlym |
| Kyowa Kirin, INC. | $72.06 | 2024-2025 | Crysvita |
| Cequr Corporation | $58.21 | 2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $54.07 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Teva Pharmaceuticals USA, INC. | $53.91 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sanofi-Aventis U.S. LLC | $49.54 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $48.36 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Beta Bionics, INC. | $39.33 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $38.43 | 2023-2024 | Afrezza |
| Grifols USA, LLC | $31.77 | 2023-2024 | Prolastin-C Liquid |
| Inogen, INC. | $24.19 | 2023 | Inogen At Home Stationary Concentrator |
| Chiesi USA, INC. | $20.45 | 2024 | Mycapssa |
| Avvisto Therapeutics, LLC | $14.90 | 2024 | Cycloset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Pansare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.